Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when INSP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsInspire Medical adds AtriCure CEO Michael Carrel to board
Filed July 24, 2026 · Period ending July 20, 2026 · ~1 min read
Key Changes
-
medium
Michael H. Carrel, President and CEO of AtriCure (a medical device company focused on atrial fibrillation treatments), appointed as Class III director effective July 20, 2026, with term through 2027 annual meeting.
Item 5.02 verify on EDGAR → -
low
Carrel assigned to Organization and Compensation Committee and Quality, Product Supply and Technology Committee.
Item 5.02 verify on EDGAR → -
low
Compensation follows standard non-employee director policy: $70,000 annual cash retainer, $300,000 initial equity grant vesting over three years, and $200,000 annual equity grants vesting after one year.
Item 5.02 verify on EDGAR →
Summary
Inspire Medical Systems expanded its board by appointing Michael H. Carrel, the President and CEO of AtriCure, as a Class III director effective July 20, 2026. Carrel brings medical device industry experience from his leadership of AtriCure, which focuses on atrial fibrillation treatments.
He will serve on two board committees: Organization and Compensation, and Quality, Product Supply and Technology. The appointment follows Inspire's standard non-employee director compensation structure, with $70,000 in annual cash retainers and equity grants totaling $300,000 initially (vesting over three years) and $200,000 annually thereafter (vesting after one year). This is a routine board expansion adding industry expertise, with no immediate operational or strategic implications disclosed.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Mr. Carrel is eligible to participate in the Company’s Non-Employee Director Compensation Policy, which provides for: (i) an annual cash retainer of $55,000 for serving on the Board, earned on a quarterly basis; (ii) an annual cash retainer of $7,500 for serving on the Organization and Compensation Committee, earned on a quarterly basis; (iii) an annual cash retainer of $7,500 for serving on the Quality, Product Supply and Technology Committee, earned on a quarterly basis (iv) an initial equity-based award of restricted stock units to acquire shares of the Company’s common stock having an aggregate fair value of $300,000 (the “Initial Award”), which award vests in substantially equal annual installments over three years following the grant date, subject to Mr. Carrel’s continued service on the Board through each such vesting date; and (iv) following each annual meeting of the Company’s stockholders, an annual equity-based of restricted stock units to acquire shares of the Company’s common stock having an aggregate fair value of $200,000, which award vests on the first anniversary of the date of grant, subject to Mr. Carrel’s continued service on the Board through such vesting date.
Mr. Carrel will receive total annual cash retainers of $70,000 ($55,000 base plus $7,500 for each of two committees), paid quarterly. He will receive an initial equity grant of restricted stock units worth $300,000 vesting over three years, and annual equity grants worth $200,000 vesting after one year following each annual meeting. The compensation follows the company's standard non-employee director policy.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 27, 2026 · How we verify